In vivo pharmacokinetic studies of albendazole nanoparticulate oral formulations for improved bioavailability

International Journal of Green Nanotechnology: Biomedicine

Volumn 2, Issue 1, 2010, Pages

  Ravichandran, R ^a  

^a National Council of Educational Research and Training India   (India)

Author keywords

Albendazole; Bioavailability; Nanosuspensions; Pharmacokinetics

Indexed keywords

ALBENDAZOLE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISSOLUTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG SOLUBILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIPOPHILICITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TABLET;

EID: 77956886428     PISSN: 1943085X     EISSN: 19430906     Source Type: Journal    
DOI: 10.1080/1943085x.2010.488200     Document Type: Article

References (57)

1. Cook, G. C. Use of benzimidazole chemotherapy in human helminthiases: indications and efficacy. Parasitol. Today 1990, 6, 133-136.
2. Wen, H.; New, R. R. C.; Craig, P. S. Diagnosis and treatment of human hydatidosis. Br. J. Clin. Pharm. 1993, 35,565-574.
3. WHO Informal Working Group on Echinococcosis. Guidelines for treatment of cystic alveolar echinococcosis in humans. Bull. WHO 1996, 74, 231-242.
4. Misra, P. K.; Kumar, A.; Agarwal, U.; Jagota, S. C. A comparative clinical trial of albendazole vs metronidazole in giardiasis. Indian Pediatr. 1995, 32, 291-294.
5. Lecuit, N.; Oksenhendler, E.; Sarfati, C. The use of albendazole for disseminated microsporidian infection in patients with AIDS. Clin. Infect. Dis. 1994, 19, 332-333.
6. Lopez-Garcia, M. L.; Torrado-Duran S.; Torrado Duran, J.; Martinez, A. R.; Bolas, F. Albendazole versus ricobendazole against enteral and parenteral stages of Trichinella spiralis in mice. Int. J. Parasitol. 1997, 27, 781-785.
7. Keramidas, D.; Mavridis, G.; Soutis, M.; Passalidis, A. Medical treatment of pulmonary hydatidosis: complications and surgical management. Pediatr. Surg. Int. 2004, 19,774-776.
8. Del-Brutto, O. H.; Sotelo, I.; Raman, G. C. Therapy for neurocysticercosis: a reappraisal. Clin. Infect. Dis. 1993,17,730-733.
9. Gil-Grande, L. A.; Rodriguez-Caabeiro, F.; Prieto, J. G.; Sánchez-Ruano, J. J.; Brasa, C. Randomised controlled trial of efficacy of Albendazole in intra abdominal hydatid disease. Lancet 1993, 342, 1269-1272.
10. Van-Nieuwkerk, K. M. J.; Veenstra, J.; Wassenaar, R. P.; Blaauwgeers, H. L.; Geraedts, A. A.; Kroes, H. Pancreatitis causes by rupture of liver hydatid cyst. Eur. J. Gastroenterol. Hepatol. 1993, 5, 563-565.
11. Yasawy, M. I.; ALKarawi, M. A.; Are, M. Combination of praziquantel and albendazole in the treatment of hydatid disease. Trop. Med. Parasitol. 1993, 44, 192-195.
12. Amidon, G. L.; Lennernas, H.; Shah, V. P.; Crison, J. R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 1995, 12, 413-420.
13. Jung, H.; Medina, L.; Garcia, L.; Fuentes, I.; Esparza, R. M. Absorption studies of albendazole and some physicochemical properties of the drug and its metabolite, albendazole sulphoxide. J. Pharm. Pharmacol. 1998, 50, 43-48.
14. Torrado, S. S.; Lopez, M. L.; Torrado, G.; Bolas, G.; Torrado, S.; Cadorniga, R. A novel formulation of albendazole solution: oral bioavailability and efficacy evaluation. Int. J. Pharm. 1997, 156, 181-187.
15. Torrado, S.; Torrado, S.; Torrado, J. J.; Cadorniga, R. Preparation, dissolution and characterization of albendazole solid dispersions. Int. J. Pharm. 1996, 140, 247-250.
16. Jacobs, C.; Kayser, O.; Muller, R. H. Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide. Int. J. Pharm. 2000, 196, 161-164.
17. Kayser, O.; Olbrich, C.; Yardley, V.; Kiderlen, A. F.; Croft, S. L. Formulation of amphotericin B as nanosuspension for oral administration. Int. J. Pharm. 2003, 254, 73-75.
18. Ravichandran, R. Nanoparticlesindrugdelivery:potential green nanobiomedicine applications. Int. J. Green Nanotechnol. Biomed. 2009, 1, B108-B130.
19. Ravichandran, R. Nanotechnology-based drug delivery systems. NanoBiotechnology 2009, 5(1), 17-33.
20. Chen, X.; Young, T. J.; Sarkari, M.; Williams, R. O.; Johnston K. P. Preparation of cyclosporine: a nanoparticles by evaporative precipitation into aqueous solution. Int. J. Pharm. 2002, 242, 3-14.
21. Muller, R. H.; Jacobs, C.; Kayser, O. Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future. Ad. Drug Del. Rev. 2001, 47, 3-19.
22. Weder, H. G.; van Hoogevest, P. Nanosuspensions for intravenous administration. US 5726164, 1998.
23. Muller, R. H.; Jacobs, C. Buparvaquone mucoadhesive nanosuspensions: Preparation, optimisation and longterm stability. Int. J. Pharm. 2002, 237, 151-161.
24. Rabinow, B. E. Nanosuspensions in drug delivery. Nat. Rev. Drug. Discov. 2004, 3, 785-96.
25. Keck, C. M.; Muller, R. H. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenization. Eur. J. Pharm. Biopharm. 2006, 62, 3-16.
26. Liversidge, G. G.; Cundy, K. C. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int. J. Pharm. 1995, 125, 91-97.
27. Jinno, J.; Naoki, K.; Miyake, M.; Yamada, K.; Mukia, T.; Odomi, M.; Togu-chi, H.; Liversidge, G. G.; Higaki, K.; Kimura, T. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J. Control. Release 2006, 111,56-64.
28. Liversidge, G. G.; Conzentino, P. Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int. J. Pharm. 1995, 125, 309-313.
29. Rao, Y. M.; Kumar, M. P.; Apte, S. Formulation of nanosuspensions of albendazole for oral administration. Curr. Nanosci. 2008, 4, 53-58.
30. PavanKumar, M.; MadhusudanRao, Y.; Apte, S. Improvedbioavailabilityofalbendazolefollowingoraladministration of nanosuspension in rats. Curr. Nanosci. 2007, 3, 191-194.
31. Davis, A.; Dixon, H.; Pawlowski, Z. S. Multicentre clinical trials of benzimidazole-carbamates in human cystic echinococcosis(phase2).Bull.W.H.O.1989,67,503-508.
32. Horton, R. J. Albendazole in treatment of human cystic echinococcosis: 12 years of experience. Acta Trop. 1997,64,79-93.
33. Jung, H.; Medina, L.; Garcia, L.; Fuentes, I.; Moreno-Esparza, R. Absorption studies of albendazole and some physicochemical properties of the drug and its metabolite albendazole sulphoxide. J. Pharm. Pharmacol. 1998,50,43-48.
34. Kohri, N.; Yamayoshi, Y.; Xin, H.; Iseki, K.; Sato, N.; Todo, S.; Miyazaki, K. Improving the oral bioavailability of albendazole in rabbits by the solid dispersion technique. J. Pharm. Pharmacol. 1999, 51, 159-164.
35. del Estal, J. L.; Alvarez, A. I.; Villaverde, C.; Coronel, P.; Fabra, S.; Prieto, J. G. Effect of surfactants on albendazole absorption. J. Pharm. Biomed. Anal. 1991, 9, 1161-1164.
36. del Estal, J. L.; Alvarez, A. I.; Villaverde, C.; Justel, A.; Prieto, J. G. Increased systemic bioavailability of albendazol when administered with surfactants in rats. Int. J. Pharm. 1994, 102, 257-260.
37. del Estal, J. L.; Alvarez, A. I.; Villaverde, C.; Prieto, J. G. Comparative effects of anionic, natural bile acid surfactants and mixed micelles on the intestinal absorption of the anthelmintic albendazole. Int. J. Pharm. 1993, 91, 105-109.
38. Wen, H.; New, R. R. C.; Muhmut, M.; Wang, J. H.; Wang, Y. H.; Zhang, J. H.; Shao, Y. M.; Craig, P. S. Pharmacology and efficacy of liposome-entrapped albendazole in experimental secondary alveolar echinococcosis and effect of co-administration with cimetidine. Parasitology 1996, 13,111-121.
39. Evrard, B.; Chiap, P.; DeTullio, P.; Ghalmi, F.; Piel, G.; van Hees, T.; Crommen, J.; Losson, B.; DaLattre, L. Oral bioavailability in sheep of albendazole from a suspension and from a solution containing hydroxypropyl beta-cyclodextrin. J. Control. Release 2002, 85, 45-50.
40. Piel, G.; Evrard, B.; Van Hees, T.; Llabres, G.; Delattre, L. Development of a parenteral and of an oral formulation of albendazole with cyclodextrins. Stp. Pharma. Sci. 1999, 9, 257-260.
41. Awadzi, K.; Hero, M.; Opoku, N. O.; Büttner, D. W.; Coventry, P. A.; Prime, M. A.; Orme, M. L. E.; Edwards, G. The chemotherapy of onchocerciasis XVII. A clinical evaluation of albendazole in patients with onchocerciasis; effects of food and pretreatment with ivermectin on drug response and pharmacokinetics. Trop. Med. Parasitol. 1994, 45, 203-208.
42. Homeida, M.; Leahy, W.; Copeland, S.; Ali, M. M.; Harron, D. W. Pharmacokinetic interaction between praziquantel and albendazole in Sudanese men. Ann. Trop. Med. Parasitol. 1994, 88, 551-559.
43. Lange, H.; Eggers, R.; Bircher, J. Increased systemic availability of albendazole when taken with a fatty meal. Eur. J. Clin. Pharmacol. 1988, 34, 315-317.
44. Nagy, J.; Schipper, H. G.; Koopmans, R. P.; Butter, J. J.; van Boxtel, C. J.; Kager, P. A. Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability. Am. J. Trop. Med. Hyg. 2002, 66, 260-263.
45. Schipper, H. G.; Koopmans, R. P.; Nagy, J.; Butter, J. J.; Kager, P. A.; van Boxtel, C. J. Effect of dose increase or cimetidine co-administration on albendazole bioavailability. Am. J. Trop. Med. Hyg. 2000, 63, 270-273.
46. Mingjie, W.; Shuhua, X.; Junjie, C.; Bin, L.; Cheng, F.; Weixia, S.; Hotez, P. Albendazole-soybean oil emulsion for the treatment of human cystic echinococcosis: evaluation of bioavailability and bioequivalence. Acta Trop. 2002, 83,177-181.
47. McKellar, Q. A.; Scott, E. W. The benzimidazole anthelmintic agent: a review. J. Vet. Pharmacol. Ther. 1990, 13,223-247.
48. Delatour, P.; Benoit, E.; Besse, S. Comparative enantioselectivity in the sulphoxidation of albendazole in man, dogs and rats. Xenobiotica 1991, 21, 217-221.
49. Lopez-Garcia, M. L.; Torrado, S.; Torrado, S.; Martinez, A. R.; Bolas, F. Methimazole-mediated enhancementofalbendazolebioavailabilityandanthelminticeffects against parenteral stages of Trichinella spiralis in mice: the influence of the dose-regime. Vet. Parasitol. 1998, 75, 209-219.
50. Gyurik, R. J.; Chow, A. W.; Zaber, B.; Bruner, E. L.; Miller, J. A.; Villani, A. J.; Petka, L. A.; Parish, R. C. Metabolism of albendazole in cattle, sheep, rats and mice. Drug Metab. Dispos. 1981, 9, 503-08.
51. Pedersen, M. The bioavailability difference between genuine cyclodextrin inclusion complexes and freeze-dried or ground drug-cyclodextrin samples may be due to super saturation differences. Drug Dev. Ind. Pharm. 1997, 23, 331-335.
52. Liversidge, G. G.; Conzentino, P. Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int. J. Pharm. 1995, 125, 309-313
53. Adams, M. L.; Lavasanifar, A.; Kwon, G. S. Amphiphilic block copolymers for drug delivery. J. Pharm. Sci. 2003, 92, 1343-1355.
54. Rigter I. M.; Schipper, H. G. Koopmans, R. P. van Kan, H. J. M. Frijlink, H. W. Kager, P. A. Guchelaar H.-J. Relative bioavailability of three newly developed albendazole formulations: a randomized crossover study with healthy volunteers. Antimicrob. Agents Chemother. 2004, 48,1051-1054.
55. García, J. J.; Francisco Bolása, F.; Torrado, J. J. Bioavailability and efficacy characteristics of two different oral liquid formulations of albendazole. Int. J. Pharmaceut. 2003,250,351-358.
56. Garcia J. J.; Bolás-Fernándeza, F.; Torrado, J. J. Quantitative determination of albendazole and its main metabolites in plasma. J. Chromatogr. B Biomed. Sci. Appl. 1999,723,265-271.
57. Torrado, S.; Torrado, S.; Cadorniga, R.; Torrado, J. J. Formulation parameters of albendazole solution. Int. J. Pharm. 1996, 140, 45-50.